View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Aptar Pharma
14 June 2017

Aptar Pharma Adds Nasal Pump Manufacturing Capacity in North America

Manufacturing capacity for child-resistant and senior-friendly nasal pumps

Aptar Pharma added manufacturing capacity in North America for its Child-Resistant (CR) and Senior-Friendly (SF) Classic Nasal Pumps.

Aptar Pharma, a manufacturer of drug delivery systems for nasal applications, installed a new assembly machine in its Congers site, NY.

Effective April 2017, the new machine was transferred from Aptar Pharma’s plant in Southern Germany to the Congers site. This represents an important step in Aptar Pharma’s history, bringing its manufacturing capacity closer to the target market for which this pump has been successfully established.

Aptar Pharma’s CR technology platform was developed primarily for the US market when, in 2012, the US Consumer Product Safety Commission (CPSC) issued a rule requiring CR packaging for any over-the-counter or drug product containing the equivalent of 0.08mg or more of imidazoline (16 CFR Part 1700.14), a formulation widely used in nasal decongestant topical sprays.

Less than two years after the announcement, Aptar Pharma introduced its newly-engineered CR / SF nasal spray pump to the US market, which successfully matched the CPSC’s requirements. This feat once more underscored Aptar Pharma’s worldwide reputation as an innovative leader and trusted partner in the pharmaceutical industry.

Aptar Pharma’s Child-Resistant Feature for nasal sprays effectively combines CR and SF with its intuitive and widely-accepted squeeze-and-turn technology. Positive market feedback and increasing demand for the Child-Resistant Feature over the last two years demonstrates that Aptar Pharma’s CR / SF technology is one of the best-in-class solutions available on the US market. A large number of current major brands of nasal decongestant topical sprays in the US come with Aptar Pharma’s Child-Resistant Feature.

Aptar Pharma’s North America President Alex Theodorakis said: "We are pleased to welcome the arrival of Aptar Pharma’s CR assembly machine to our recently-expanded Congers, NY, manufacturing site. This added manufacturing capacity enables us to offer the production of this key CR / SF Feature to our customers domestically.

"Being closer to our customers continues to be of strategic importance to Aptar Pharma, and this new initiative enables us to continue to support our important North American marketplace and increase our demand reactivity."


Image: Aptar Pharma Congers site, NY – Courtesy of Aptar Pharma

Aptar Pharma is one of the leading suppliers of aerosol metering valves, a key sub-system of pressurised metered dose inhalers (pDMI) that enables accurate and...
Worth an estimated >2bn in 2009, the nasally administered systemic drugs market has an increasing generics sector, is placing greater emphasis on patient compliance and...
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology